Evidence map›Paper›PMID 42346144›Full record

ReviewCells2026

The Interplay of Splicing and Metabolism in Cancer.

Dillon M Voss, Yange Cui, Peter S Klein

Abstract readReview
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dillon M VossRenaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
Yange CuiDivision of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-0864-3735
Peter S KleinDivision of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2011-8538

Funding

Mitochondrial dysfunction driven by splicing factor mutations in MDSR01DK141594 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S, WALLACE, DOUGLAS C · 2025 to 2025
$3.2M
Targeting mitophagy through PINK1 splicing in MDSR01DK143081 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI PETER S KLEIN, Eunice Sue Wang · 2026 to 2026
$756k
NIDDK NIH HHS R01 DK141594NIDDK NIH HHS R01 DK143081
6 · The paper itself

Abstract

Aberrant RNA splicing and metabolic reprogramming are defining hallmarks of cancer that were historically studied as parallel processes. Increasing evidence now reveals extensive crosstalk between these pathways, whereby RNA splicing reshapes metabolic circuits, and metabolic states reciprocally influence splice-site selection and spliceosome activity. In this review, we synthesize recent mechanistic insights into how splicing programs regulate metabolic adaptation across diverse cancer contexts. We discuss recurrent oncogenic mutations in spliceosomal components and dysregulation of RNA-binding proteins (RBPs) that drive alternative splicing events in key metabolic regulators, which promote metabolic plasticity required for tumor growth. We further examine how metabolites and nutrient-sensing pathways directly modulate splicing factor activity, spliceosome dynamics, and RNA processing. We also summarize a new mechanism of mitochondrial quality control mediated by retrograde signals from mitochondria to the spliceosome to enhance mitophagy of dysfunctional mitochondria.

Indexed as

NeoplasmsRNA SplicingAlternative SplicingAnimalsHumansMetabolic ReprogrammingMitochondriaMitophagyRNA-Binding ProteinsSpliceosomesRNA-Binding ProteinscancerleukemiametabolismmitophagymyelodysplasiaPINK1pyruvate kinaseretrograde signalingspliceosomesplicing

Identifiers

PMID42346144
PMCPMC13296549

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.